Introduction
============

Atherosclerotic cardiovascular disease is the leading cause of mortality worldwide ([@b1-ijmm-42-05-2489],[@b2-ijmm-42-05-2489]). The cardiomyocytes (CMs) in patients with acute myocardial infarction (AMI) undergo cell death, alteration of cell cycle, and abrupt mitochondrial oxidative metabolism in either ischemic or hypoxic conditions ([@b3-ijmm-42-05-2489]-[@b5-ijmm-42-05-2489]). Therefore, antiplatelet agents, anticoagulation agents, and emergent coronary revascularization are often used to treat patients with acute coronary syndrome ([@b6-ijmm-42-05-2489]).

Apoptotic cell death is important in myocardial damage following AMI, which may lead to malignant arrhythmia, heart failure and cardiac death ([@b7-ijmm-42-05-2489],[@b8-ijmm-42-05-2489]). During hypoxia and reoxygenation injury, CMs exhibit typical morphological characteristics of apoptotic nuclei, including membrane blebs, myofibillary disarrangement, chromatin condensation, and peripheral margination of mitochondria ([@b3-ijmm-42-05-2489]). Increased myocardial apoptosis has also been found in autopsies of patients who have succumbed to AMI and multi-vessel coronary artery diseases ([@b9-ijmm-42-05-2489],[@b10-ijmm-42-05-2489]). Furthermore, changes in several pro-apoptotic and anti-apoptotic mediators have been noted in ischemic or hypoxic CMs *in vivo*, in isolated animal hearts, and in humans ([@b5-ijmm-42-05-2489],[@b7-ijmm-42-05-2489],[@b8-ijmm-42-05-2489],[@b11-ijmm-42-05-2489],[@b12-ijmm-42-05-2489]).

Unlike traditional Sanger sequencing technology, next-generation sequencing (NGS) provides rapid analyses of large quantities of genomic information, including DNAs, mRNAs, microRNAs (miRNAs), and non-coding RNAs ([@b13-ijmm-42-05-2489],[@b14-ijmm-42-05-2489]). Using NGS in combination with bioinformatics analyses, whole exon sequencing has been performed in previous studies to identify a wide spectrum of genetic mutations in several scientific fields ([@b13-ijmm-42-05-2489],[@b14-ijmm-42-05-2489]). NGS has also been used to identify novel genetic regulations in basic and clinical research ([@b15-ijmm-42-05-2489],[@b16-ijmm-42-05-2489]), and it has been used in the genetic diagnosis of congenital heart diseases and inherited cardiac dysrhythmia ([@b16-ijmm-42-05-2489],[@b17-ijmm-42-05-2489]).

Although several studies have investigated the signaling pathways and cellular responses of CMs in ischemic or hypoxic conditions, the regulation of genetic expression with regard to hypoxia-related apoptosis is complex and remains to be fully elucidated ([@b18-ijmm-42-05-2489]-[@b20-ijmm-42-05-2489]). Therefore, the present study was designed to perform a comprehensive investigation of various genetic expression changes in hypoxic human cardiomyocytes using NGS and bioinformatic analyses.

Materials and methods
=====================

Cell culture
------------

The AC16 human cardiomyocyte cell line, purchased from EMD Millipore (Billerica, MA, USA), was cultured following standard manufacturer protocol. The cells (1×10^6^ cells/well) were seeded in 10% FBS (Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA) and DMEM/F-12 medium (Sigma-Aldrich; Merck KGaA, Darmstadt, Germany) and allowed to grow overnight. The AC16 CMs were then incubated in either a normoxic condition (37°C, 20% O~2~ and 5% CO~2~) or hypoxic condition (37°C, 1% O~2~ and 5% CO~2~) for 24 h. The hypoxic condition was maintained in a physiological oxygen workstation (InvivO2 400; Baker Ruskinn, Sanford, ME, USA).

Flow cytometry and detection of apoptosis
-----------------------------------------

The cells were analyzed using an Annexin V-FITC Early Apoptosis Detection kit (Cell Signaling Technology, Inc., Danvers, MA, USA) and a BD Accuri C6 Plus flow cytometer (BD Biosciences, Franklin Lakes, NJ, USA) as previously reported ([@b21-ijmm-42-05-2489]).

RNA sequencing
--------------

Total RNAs from the normoxic and hypoxic AC16 CMs were extracted with TRIzol reagent (Invitrogen, Thermo Fisher Scientific, Inc.) following the manufacturer\'s standard protocol. The purified RNA was measured at OD260nm with an ND-1000 spectrophotometer (Nanodrop Technologies; Thermo Fisher Scientific, Inc., Wilmington, DE, USA) and qualitatively analyzed with an RNA 6000 LabChip kit (Agilent Technologies, Inc., Santa Clara, CA, USA) and the Bioanalyzer 2100 (Agilent Technologies, Inc.).

Library preparation and deep sequencing were performed according to the manufacturer\'s protocol (Illumina, Welgene Biotechnology Company, Taipei, Taiwan), as described in our previous reports ([@b15-ijmm-42-05-2489],[@b22-ijmm-42-05-2489]). For small RNA sequencing, following reverse transcription of total RNA, cDNA with sizes indicating 18-40-nucleotide RNA fragments (140-155 nucleotides in length with both adapters) was extracted and sequenced on the Illumina instrument (75 single-end cycles). Following trimming or removing low-quality data using Trimmomatic (version 0.36) ([@b23-ijmm-42-05-2489]), the qualified reads were analyzed using miRDeep2 software (version 2.0.0.8) ([@b24-ijmm-42-05-2489]) and the human genome from the University of California Santa Cruz (UCSC) database (<https://genome.ucsc.edu/>). The miRNAs with low levels \[\<1 normalized read per million (rpm)\] in both hypoxic and normoxic cells were excluded. For transcriptome sequencing, the library constructed with the SureSelect Strand Specific RNA Library Preparation kit (Agilent Technologies, Inc.) was sequenced with the TruSeq SBS kit on the Solexa platform (Illumina NextSeq 500; 75 cycles, single-end). Following trimming or removing low-quality data using Trimmomatics ([@b23-ijmm-42-05-2489]), the qualified reads were analyzed using Cufflinks ([@b25-ijmm-42-05-2489]) and the Ensembl database (<https://asia.ensembl.org/index.html>). The genes with low expression levels (\<0.3 fragment per kilobase of transcript per million mapped reads) in both hypoxic and normoxic cells were excluded.

miRNA database analyses
-----------------------

The miRmap is a web database used to predict putative genes targeted by candidate miRNAs and is available from <http://cegg.unige.ch/mirmap> ([@b26-ijmm-42-05-2489]). In the present study, a search was performed for putative targeted miRNAs from human species and miRmap scores \>99.0. A search was also performed for potential miRNA interactions in the miRmap, TargetScan (<http://www.targetscan.org/vert_71/>) and miRDB (<http://www.mirdb.org/>) databases.

Ingenuity^®^ Pathway Analysis (IPA)
-----------------------------------

IPA software (Ingenuity Systems, Redwood City, CA, USA) integrates numerous results and performs multiple analyses providing a comprehensive interpretation of a large quantity of experimental data. In the present study, IPA analysis was performed for the network analyses of candidate genes.

Gene expression omnibus (GEO) database analysis
-----------------------------------------------

The GEO database (<https://www.ncbi.nlm.nih.gov/geo/>) is a useful web database containing raw gene expression data from microarray studies and NGS. The present study used a GEO array (GEO accession: GDS3483) investigating the gene responses to hypoxia in primary human pulmonary microvascular endothelial cells and cardiac microvascular endothelial cells ([@b27-ijmm-42-05-2489]). Data were collected from the cardiac microvascular endothelial cells under normoxia or hypoxia (1% O~2~, 5% CO~2~, and 94% N~2~) over various durations (3, 24 and 48 h). The raw data extracted from the GEO database were re-plotted and statistically analyzed using analysis of variance (ANOVA) followed by Dunnett\'s test using GraphPad Prism^®^ 7 software (GraphPad Software, Inc., La Jolla, CA, USA).

Database for Annotation Visualization and Integrated Discovery (DAVID) analysis
-------------------------------------------------------------------------------

The DAVID (<https://david.ncifcrf.gov/>) database ([@b28-ijmm-42-05-2489]) is a useful tool for gene functional classification. It integrates data from multiple functional annotation databases, including Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway. A list of genes of interest is classified by clustering of related biological functions, signaling pathways, or diseases by calculating the similarity of global annotation profiles using an agglomeration algorithm method. The functions of differentially expressed genes were analyzed following methods used in our previous studies ([@b15-ijmm-42-05-2489],[@b22-ijmm-42-05-2489]).

Statistical analysis
--------------------

The expression levels of the genes were compared between cells treated with hypoxia for different lengths of time (3, 24 and 48 h) and normoxic cells using ANOVA, followed by Dunnett\'s test. P*\<*0.05 (two-tailed) was considered to indicate a statistically significant difference.

Results
=======

Gene expression profiling and miRNA changes in hypoxic AC16 CMs
---------------------------------------------------------------

As shown in [Fig. 1A](#f1-ijmm-42-05-2489){ref-type="fig"}, RNAs were extracted from the cells and sent for NGS followed by bioinformatics analyses. The AC16 CMs incubated under hypoxic conditions exhibited increased apoptosis compared with the cells incubated under normoxic conditions ([Fig. 1B](#f1-ijmm-42-05-2489){ref-type="fig"}).

A volcano plot of differentially upregulated (right panel) and downregulated (left panel) gene expression in hypoxic, vs. normoxic AC16 CMs is shown in [Fig. 2A](#f2-ijmm-42-05-2489){ref-type="fig"}. Genes with −log~10~ (P-value) \>1.3 and \>2-fold changes ([Fig. 2B](#f2-ijmm-42-05-2489){ref-type="fig"}) were selected for further analyses. The small RNA-sequencing data generated with NGS were analyzed to identify potentially significant changes in miRNA profiles in the AC16 CMs under hypoxia, vs. normoxia. As shown in [Fig. 2C and D](#f2-ijmm-42-05-2489){ref-type="fig"}, 184 miRNAs were identified with \>2-fold changes (99 upregulated and 85 downregulated). Following selection of those with thresholds of \>1 rpm in both hypoxic and normoxic cells, 62 miRNAs were identified, including 30 miRNAs with \>2-fold upregulation and 32 miRNAs with \>2-fold downregulation ([Table I](#tI-ijmm-42-05-2489){ref-type="table"}).

Identification of potential miRNA-mRNA interactions in hypoxic AC16 CMs
-----------------------------------------------------------------------

The present study aimed to determine the potential miRNA-mRNA interactions in hypoxic AC16 CMs. To achieve this, the putative targets of the miRNAs with \>2-fold changes were searched ([Fig. 2D](#f2-ijmm-42-05-2489){ref-type="fig"}) from the NGS results using a miRmap database search for those with threshold miRmap scores \>99.0. The genes showing \>2-fold changes ([Fig. 2B](#f2-ijmm-42-05-2489){ref-type="fig"}) were matched with these putative targets, and, as shown in the intersection Venn diagram in [Fig. 2C](#f2-ijmm-42-05-2489){ref-type="fig"}, 24 genes were potentially involved in miRNA-mRNA interactions (15 upregulated and nine downregulated) ([Table II](#tII-ijmm-42-05-2489){ref-type="table"}).

A search was also performed for the potential miRNA-mRNA interactions of the miRNAs with \>2-fold changes in various miRNA target predicting databases. On combining the results from miRmap, TargetScan and miRDB, two miRNA-mRNA interactions were identified: hsa-miR-129-5p/*CDC42EP3* and hsa-miR-330-3p/*HELZ* ([Fig. 3](#f3-ijmm-42-05-2489){ref-type="fig"}). However, although hsa-miR-129-5p and hsa-miR-330-3p were significantly upregulated in hypoxic CMs, no significant differences in the expression levels of *CDC42EP3* or *HELZ* were noted between the hypoxic and normoxic CMs.

Validation of the differentially expressed genes in response to hypoxia
-----------------------------------------------------------------------

The 24 genes with potential miRNA-mRNA interactions ([Table II](#tII-ijmm-42-05-2489){ref-type="table"}) were further compared against associated array data obtained from the GEO database. Briefly, the gene expression levels in cardiac microvascular endothelial cells were extracted from the GEO database (GEO accession: GDS3483) ([@b27-ijmm-42-05-2489]). The expression levels of the genes were compared between cells treated with hypoxia over different lengths of time (3, 24 and 48 h) and those of normoxic cells. The findings were partially similar to those from the NGS CM data. In hypoxic cardiac microvascular endothelial cells, tensin 1 (*TNS1*), B-cell lymphoma 2 (BCL2)/adenovirus E1B 19 kDa protein-interacting protein 3 (*BNIP3L*), and stanniocalcin 1 (*STC1*) were significantly upregulated ([Fig. 4A](#f4-ijmm-42-05-2489){ref-type="fig"}) and transferrin receptor (*TFRC*) and methyltransferase like 7A (*METTL7A*) were significantly downregulated ([Fig. 4B](#f4-ijmm-42-05-2489){ref-type="fig"}). However, unlike the findings based on NGS CM data, Calcium/calmodulin dependent protein kinase 1D (*CAMK1D*) was significantly downregulated.

GO annotations and KEGG pathway analyses of DEGs in hypoxic AC16 CMs
--------------------------------------------------------------------

Network analyses of the 24 genes with potential miRNA-mRNA interactions were performed using IPA software. The top three networks associated with genes targeted by miRNAs differentially expressed in hypoxic AC16 CMs are listed in [Table III](#tIII-ijmm-42-05-2489){ref-type="table"}. In network 1 ([Fig. 5A](#f5-ijmm-42-05-2489){ref-type="fig"}), 14 targeted genes (iodothyronine deiodinase 2, solute carrier family 2 member 5, apolipoprotein L6, histone deacetylase 11, *STC1*, membrane metalloendopeptidase (*MME*), chac glutathione specific γ-glutamylcyclotransferase 1, apelin, *TFRC*, CD4 molecule, hypoxia inducible factor 3 α subunit, *BCL2*, dematin actin binding protein, and solute carrier family 6 member 13) were associated with free radical scavenging, small molecule biochemistry, and carbohydrate metabolism. In network 2 ([Fig. 5B](#f5-ijmm-42-05-2489){ref-type="fig"}), seven targeted genes (solute carrier family 7 member 11, activin A receptor like type 1, *BNIP3L*, *MME*, *METTL7A*, *TNS1*, and G protein-coupled receptor 68) were associated with cancer, organismal injury and abnormalities, and cell death and survival. In network 3, only *CAMK1D* was associated with carbohydrate metabolism, small molecule biochemistry, and digestive system development and function. Two genes (complement C1q like 1 and transmembrane protein 144) were not involved in these networks.

Functional analysis of the DEGs from mRNA sequencing was also performed by DAVID biological process analysis ([Fig. 6](#f6-ijmm-42-05-2489){ref-type="fig"}). The top four biological processes of these genes were cellular response to hypoxia (12 genes), brown fat cell differentiation (seven genes), positive regulation of apoptotic process (13 genes), and response to hypoxia (nine genes). The protein-coding genes specifically associated with apoptosis, cell proliferation inhibition, and cell cycle arrest were also analyzed with a heatmap ([Fig. 7](#f7-ijmm-42-05-2489){ref-type="fig"}).

The top 20 KEGG pathways of dysregulated genes were identified using mRNA sequencing data ([Table IV](#tIV-ijmm-42-05-2489){ref-type="table"} and [Fig. 8](#f8-ijmm-42-05-2489){ref-type="fig"}). The legionellosis (fold enrichment=7.11), regulation of lipolysis in adipocytes (fold enrichment=6.86), and glycolysis/gluco-neogenesis (fold enrichment=5.73) pathways were significantly enriched in the hypoxic CMs.

Discussion
==========

Differential gene expression with altered signaling pathways has been reported in CMs responding to hypoxic/ischemic conditions ([@b3-ijmm-42-05-2489],[@b29-ijmm-42-05-2489],[@b30-ijmm-42-05-2489]). The reciprocal regulation of miRNAs and

mRNA in human CMs from patients with heart failure has also been investigated using microarray analysis ([@b31-ijmm-42-05-2489]). The present study comprehensively surveyed the differential expression of mRNAs and miRNAs and potential mRNA-miRNA interactions using NGS techniques and bioinformatics.

miRNAs are short, small non-coding RNAs, which regulate gene expression via several post-transcriptional processes ([@b32-ijmm-42-05-2489]). Hypoxia is a stress condition that may provoke multiple biological and molecular regulatory networks associated with apoptosis, cell proliferation, and alterations in metabolism ([@b32-ijmm-42-05-2489]). Previous studies have suggested that miRNAs may potentially be used as novel diagnostic makers and therapeutic targets for hypoxic CMs in clinical scenarios, including AMI ([@b33-ijmm-42-05-2489]). The present study found 62 miRNAs with \>2-fold changes in hypoxic CMs. Based on the miRNA-mRNA interactions predicted using miRmap, TargetScan and miRDB databases, hsa-miR-129-5p and hsa-miR-330-3p were identified as having the highest potential of becoming such biomarkers. The overexpression of miR-129-5p inhibits cell proliferation in smooth muscle cells, glioblastoma multiforme cells, gastric cancer cells, and H9C2 CMs ([@b34-ijmm-42-05-2489]-[@b37-ijmm-42-05-2489]). Previous experimental studies have noted wingless-type MMTV integration site family member 5A, collagen, type I, a1, and cyclin-dependent kinase 6 to be the targets of miR-129-5p ([@b34-ijmm-42-05-2489]-[@b37-ijmm-42-05-2489]). The overexpression of miR-330 has been found to inhibit cell proliferation through B cell-specific Moloney murine leukemia virus integration site 1, E2F transcription factor 1 and musashi RNA binding protein 1 in osteosarcoma cells, gastric cells, and prostate cancer cells, respectively ([@b38-ijmm-42-05-2489]-[@b40-ijmm-42-05-2489]). However, miR-330 has also found to increase cell proliferation by regulating SH3-domain GRB2-like 2 and WNT signaling pathways in human glioblastoma cells and vascular endothelial cells, respectively ([@b41-ijmm-42-05-2489],[@b42-ijmm-42-05-2489]). Although the expression levels of these genes exhibited no significant changes in AC16 CMs exposed to hypoxia, the downstream regulatory mechanisms of hsa-miR-129-5p and hsa-miR-330-3p in hypoxic CMs warrant further investigation.

The present study identified 24 genes with significant changes and potential miRNA-mRNA interactions. These genes were associated with important cellular functions, including cell proliferation, apoptosis, and carbohydrate metabolism. Using the gene expression profiles of cardiac microvascular endothelial cells obtained from the GEO database, it was possible to validate the significant upregulation of *TNS1*, *BNIP3L* and *STC1,* and the significant downregulation of *TFRC* and *METTL7A* in response to hypoxia. *CAMK1D* exhibited paradoxical changes in different cells.

TNS1 is a focal adhesion molecule which serves as a scaffold for cell mobility and adhesion through binding to fibronectin and β1-integrin ([@b43-ijmm-42-05-2489],[@b44-ijmm-42-05-2489]). The overexpression of *TNS1* has been found to contribute to the invasion and metastasis of breast cancer cells ([@b45-ijmm-42-05-2489]). TNS1 may also be involved in the micro-environmental changes that occur in the myocardium during hypoxia.

Programmed cell death may occur in CMs via the extrinsic cytokine death pathway or the intrinsic mitochondrial pruning pathway ([@b46-ijmm-42-05-2489],[@b47-ijmm-42-05-2489]). The BNIP3 and BNIP3-like (BNIP3L, also known as NIP3-like protein X, NIP3L, or NIX), belong to the pro-apoptotic Bcl-2 protein family and are mitochondrial stress sensors ([@b48-ijmm-42-05-2489]). They can promote mitophagy and autophagy in response to hypoxia ([@b49-ijmm-42-05-2489],[@b50-ijmm-42-05-2489]). Upregulated BNIP3 and BNIP3L trigger apoptosis in conditions which include myocardial hypertrophy and are important in cardiac remodelling ([@b51-ijmm-42-05-2489],[@b52-ijmm-42-05-2489]). Therefore, these pathways have been investigated for their potential role in inhibiting ischemic CM apoptosis ([@b53-ijmm-42-05-2489]). Similarly, the present study found *BNIP3L* to be upregulated in hypoxic CMs and cardiac microvascular endothelial cells.

STC1, an endogenous glycoprotein, has anti-inflammatory and anti-oxidative effects through the uncoupling protein (UCP) family in mice kidney and lung injuries ([@b54-ijmm-42-05-2489],[@b55-ijmm-42-05-2489]). However, its main role in CMs remains to be elucidated. STC1 has been found to be significantly increased in patients with dilated cardiomyopathy, but normalizes following treatment using a left ventricular assist device ([@b56-ijmm-42-05-2489]). STC1 inhibits super-oxide generation via the induction of UCP3 in CMs, which may ameliorate angiotensin II-mediated cardiac injury ([@b57-ijmm-42-05-2489]). However, the cardiotoxic effects of STC1 also appear to be mediated via mitochondrial injuries through loss of integrity of the mitochondrial membrane, increased mitochondrial calcium levels, and reactive oxygen species production ([@b58-ijmm-42-05-2489]). In the present study, *STC1* was upregulated in hypoxic CMs and cardiac microvascular endothelial cells. Whether this up regulation of *STC1* was associated with anti-oxidative effects or pro-oxidative effects warrants further investigation.

The present study revealed significant downregulation of *TFRC* and *METTL7A* in hypoxic CMs and cardiac microvascular endothelial cells. Previous studies have shown that either iron overloading or deficiency in CMs were associated with cardiotoxicity and heart failure. In mice, the lack of TFRC results in poor cardiac and mitochondrial function, and early death ([@b59-ijmm-42-05-2489]). Decreased expression of *TFRC* has been associated with reduced pulmonary smooth muscle cell proliferation in hypoxia ([@b60-ijmm-42-05-2489]). *METTL7A* has been recognized as a novel tumor suppressor gene ([@b61-ijmm-42-05-2489]). The actual role of the downregulation of *METTL7A* in CMs and cardiac microvascular endothelial cells in response to hypoxia remains uncertain and requires further investigation.

CAMK1D is a key regulator of granulocyte function and has been associated with newly-developed type 2 diabetes mellitus in Japan ([@b62-ijmm-42-05-2489],[@b63-ijmm-42-05-2489]). The overexpression of *CAMK1D* results in increased cell proliferation and epithelial-mesenchymal transition activity in breast epithelial cells ([@b64-ijmm-42-05-2489]). In the present study, it was found that *CAMK1D* was significantly upregulated in hypoxic CMs but significantly downregulated in hypoxic cardiac microvascular endothelial cells. Although the reason for this paradoxical finding remains to be fully elucidated, it was hypothesized that the overexpression of *CAMK1D* in hypoxic CMs may be involved in alterations in carbohydrate metabolism and cell detachment.

In conclusion, the present study reports on the differentially upregulated/downregulated mRNAs and miRNAs in hypoxic human CMs ([Fig. 9](#f9-ijmm-42-05-2489){ref-type="fig"}). An improved understanding of the mRNA and miRNA profiles, in addition to the potential miRNA-mRNA interactions, in hypoxic CMs, enables the development of novel diagnostic tools and therapeutic strategies for hypoxic human CMs as is found in AMI.
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![Investigating hypoxia-related changes in AC16 CMs. (A) Flowchart showing the methods for investigating various genetic expression changes in hypoxic AC16 CMs using next-generation sequencing and bioinformatics approaches. (B) AC16 CMs (5×10^5^) were incubated in either a normoxic (control) or hypoxic condition for 24 h, and analyzed using a flow cytometer following staining with fluorescein isothiocyanate-conjugated Annexin V and propidium iodide. Increased apoptosis was noted in the hypoxic AC16 CMs. miRNA, microRNA; CMs, cardiomyocytes; DAVID, Database for Annotation, Visualization and Integrated Discovery; GEO, Gene expression omnibus; KEGG, Kyoto Encyclopedia of Genes and Genomes; IPA, Ingenuity^®^ Pathway Analysis.](IJMM-42-05-2489-g00){#f1-ijmm-42-05-2489}

![Potential miRNA-mRNA interactions in hypoxic AC16 CMs. (A) Volcano plot of −log~10~ (P-value), vs. log~2~ (fold change) shows differentially upregu-lated and downregulated genes in hypoxic, vs. normoxic AC16 CMs; genes with −log~10~ (P-value) \>1.3 and ≥2-fold changes are plotted in red (upregulated) and green (downregulated). (B) RNA-sequencing heatmap analysis showing differentially expressed genes (total 459 genes) with fold changes \>2.0. (C) Genes Venn diagram shows that 280 genes were upregulated and 179 genes were downregulated in hypoxic AC16 CMs, vs. normoxic AC16 CMs; the miRNA Venn diagram showed that there were 85 downregulated miRNAs and 99 upregulated miRNAs in hypoxic AC16 CMs, vs. normoxic AC16 CMs; the Targets Venn diagram revealed the putative gene targets of the miRNAs with \>2-fold changes predicted with miRmap database with threshold of miRmap scores \>99.0. The intersection Venn diagram between Genes and Targets revealed 24 genes with potential miRNA-mRNA interactions. (D) Small RNA-sequencing heatmap analysis showing differentially expressed miRNAs (total 184 miRNAs) with fold changes \>2. miRNA, microRNA; CMs, cardiomyocytes.](IJMM-42-05-2489-g01){#f2-ijmm-42-05-2489}

![Potential miRNA-mRNA interactions from miRmap, TargetScan and miRDB databases. miRmap (selection criteria: miRmap score \>99.0), TargetScan and miRDB (selection criteria: miRDB score \>99.0) were used to identify genes with potential miRNA-mRNA interactions of the miRNAs with \>2-fold changes. The intersection of three databases revealed two potential miRNA-mRNA interactions: hsa-miR-129-5p/*CDC42EP3* and hsa-miR-330-3p/*HELZ*. miRNA, microRNA.](IJMM-42-05-2489-g02){#f3-ijmm-42-05-2489}

###### 

GEO database analysis of genes with potential miRNA-mRNA interactions. The 24 genes with potential miRNA-mRNA interactions, including (A) upregulated and (B) downregulated genes in hypoxic cardiomyocytes are listed in [Table II](#tII-ijmm-42-05-2489){ref-type="table"}. They were further validated using related array data from the GEO database. The gene expression levels in cardiac microvascular endothelial cells were extracted from the GEO database (GEO accession: GDS3483), and the expression levels of the genes were compared between cells treated with hypoxia for different lengths of time (3, 24 and 48 h) and normoxic cells. ^\*^P\<0.05; \*\*P\<0.01; ^\*\*\*^P\<0.001. miRNA, microRNA; GEO, Gene Expression Omnibus.
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###### 

Networks analysis of the 24 differentially expressed genes with potential miRNA-mRNA interactions in hypoxic AC16 CMs. The network analyses of the 24 differentially expressed genes with potential miRNA-mRNA interactions in hypoxic AC16 CMs were investigated using Ingenuity^®^ Pathway Analysis software. (A) In network 1, 14 targeted genes (*DIO2*, *SLC2A5*, *APOL6*, *HDAC11*, *STC1*, *MME*, *CHAC1*, *APLN*, *TFRC*, *CD4*, *HIF3A*, *BCL2*, *DMTN*, and *SLC6A8*) were associated with free radical scavenging, small molecule biochemistry, and carbohydrate metabolism. (B) In network 2, seven targeted genes (*SLC7A11*, *ACVRL1*, *BNIP3L*, *MME*, *METTL7A*, *TNS1*, and *GPR68*) were associated with cancer, organismal injury and abnormalities, and cell death and survival. In network 3, only *CAMK1D* was associated with carbohydrate metabolism, small molecule biochemistry, and digestive system development and function. CMs, cardiomyocytes; miRNA, microRNA. Diamonds, horizontal ovals, vertical ovals, squares, rectangles, trapezoids, and inverted triangles represent enzymes, transcription regulators, transmembrane receptors, cytokines, ligand-dependent nuclear receptors, transporters, and kinases, respectively. Solid and dashed lines represent direct and indirect action, respectively. Red and green symbols represent upregulated and downregulated molecules, respectively.
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![Top 20 biological processes of the DEGs in hypoxic AC16 CMs. The top 20 biological processes of DEGs in hypoxic AC16 CMs are presented in a pie chart. numbers represent numbers of genes in the biological process. The top four biological processes of these genes were cellular response to hypoxia (12 genes), brown fat cell differentiation (seven genes), positive regulation of apoptotic process (13 genes), and response to hypoxia (nine genes). CMs, cardio-myocytes; DEGs, differentially expressed genes.](IJMM-42-05-2489-g07){#f6-ijmm-42-05-2489}

![Heatmap of the differential expression of genes specifically associated with apoptosis, cell proliferation inhibition, and cell cycle arrest in hypoxic, vs. normoxic AC16 cardiomyocytes. The upregulated and down-regulated genes are shown in red and green, respectively.](IJMM-42-05-2489-g08){#f7-ijmm-42-05-2489}

![Enrichment analysis of KEGG pathways from differentially expressed genes in hypoxic AC16 CMs. In the graph, the top 20 KEGG pathways (details listed in [Table IV](#tIV-ijmm-42-05-2489){ref-type="table"}) were plotted with −log~10~ (P*-*value), vs. fold enrichment. Higher fold enrichment values and −log~10~ (P-value) indicate that the pathway is expressed at a higher level and is more reliable. Legionellosis, regulation of lipolysis in adipocytes, glycolysis/gluconeogenesis pathways were significantly enriched in hypoxic AC16 CMs. KEGG, Kyoto Encyclopedia of Genes and Genomes; CMs, cardiomyocytes.](IJMM-42-05-2489-g09){#f8-ijmm-42-05-2489}

![Changes in miRNAs and mRNAs in hypoxic AC16 cardiomyocytes. miRNA/miR, microRNA; *TNS1*, tensin 1; *BNIP3L*, B-cell lymphoma 2-interacting protein 3 like; *STC1*, stanniocalcin 1; *TFRC*, transferrin receptor; *METTL7A*, methyltransferase like 7A.](IJMM-42-05-2489-g10){#f9-ijmm-42-05-2489}

###### 

miRNAs with significant change in hypoxic, vs. normoxic AC16 CMs.

  miRNA               Precursor        AC16 CMs hypoxia   AC16 CMs normoxia   Fold change   Up/down   
  ------------------- ---------------- ------------------ ------------------- ------------- --------- --
  hsa-miR-10b-3p      hsa-mir-10b      2.81               1.03                2.73          Up        
  hsa-miR-1276        hsa-mir-1276     4.84               1.84                2.63          Up        
  hsa-miR-142-5p      hsa-mir-142      6.08               2.18                2.79          Up        
  hsa-miR-181b-2-3p   hsa-mir-181b-2   8.33               3.33                2.50          Up        
  hsa-miR-210-3p      hsa-mir-210      392.50             122.50              3.20          Up        
  hsa-miR-210-5p      hsa-mir-210      23.52              8.49                2.77          Up        
  hsa-miR-212-5p      hsa-mir-212      6.19               1.95                3.17          Up        
  hsa-miR-224-3p      hsa-mir-224      4.61               1.15                4.01          Up        
  hsa-miR-26a-2-3p    hsa-mir-26a-2    7.43               2.75                2.70          Up        
  hsa-miR-26b-3p      hsa-mir-26b      10.80              4.47                2.42          Up        
  hsa-miR-299-5p      hsa-mir-299      27.57              10.09               2.73          Up        
  hsa-miR-3200-3p     hsa-mir-3200     10.01              3.67                2.73          Up        
  hsa-miR-330-3p      hsa-mir-330      9.79               4.70                2.08          Up        
  hsa-miR-33a-3p      hsa-mir-33a      3.15               1.26                2.50          Up        
  hsa-miR-34b-3p      hsa-mir-34b      13.39              5.28                2.54          Up        
  hsa-miR-365b-5p     hsa-mir-365b     3.60               1.15                3.13          Up        
  hsa-miR-3944-5p     hsa-mir-3944     2.48               1.15                2.16          Up        
  hsa-miR-454-5p      hsa-mir-454      14.40              5.73                2.51          Up        
  hsa-miR-485-3p      hsa-mir-485      22.84              5.51                4.15          Up        
  hsa-miR-486-3p      hsa-mir-486-1    8.78               2.64                3.33          Up        
  hsa-miR-486-3p      hsa-mir-486-2    8.89               2.29                3.88          Up        
  hsa-miR-494-3p      hsa-mir-494      18.00              8.83                2.04          Up        
  hsa-miR-548e-3p     hsa-mir-548e     6.86               3.21                2.14          Up        
  hsa-miR-550a-3p     hsa-mir-550a-1   2.48               1.03                2.41          Up        
  hsa-miR-550a-3p     hsa-mir-550a-2   2.48               1.03                2.41          Up        
  hsa-miR-550a-3p     hsa-mir-550a-3   2.48               1.03                2.41          Up        
  hsa-miR-5690        hsa-mir-5690     5.51               2.41                2.29          Up        
  hsa-miR-582-3p      hsa-mir-582      9.45               3.67                2.57          Up        
  hsa-miR-590-3p      hsa-mir-590      15.42              7.34                2.10          Up        
  hsa-miR-641         hsa-mir-641      8.21               3.90                2.11          Up        
  hsa-miR-766-3p      hsa-mir-766      10.69              5.05                2.12          Up        
  hsa-miR-92b-5p      hsa-mir-92b      11.59              5.51                2.10          Up        
  hsa-miR-98-3p       hsa-mir-98       8.78               4.36                2.01          Up        
  hsa-miR-1249-3p     hsa-mir-1249     2.48               5.28                −2.13         Down      
  hsa-miR-1262        hsa-mir-1262     1.35               3.56                −2.64         Down      
  hsa-miR-1292-5p     hsa-mir-1292     1.24               2.52                −2.03         Down      
  hsa-miR-1303        hsa-mir-1303     2.59               5.51                −2.13         Down      
  hsa-miR-1306-5p     hsa-mir-1306     1.69               4.01                −2.37         Down      
  hsa-miR-134-3p      hsa-mir-134      1.58               3.44                −2.18         Down      
  hsa-miR-1908-3p     hsa-mir-1908     1.01               2.29                −2.27         Down      
  hsa-miR-23a-5p      hsa-mir-23a      5.63               14.68               −2.61         Down      
  hsa-miR-296-3p      hsa-mir-296      1.35               3.67                −2.72         Down      
  hsa-miR-29a-5p      hsa-mir-29a      2.48               6.54                −2.64         Down      
  hsa-miR-3130-3p     hsa-mir-3130-1   1.13               4.59                −4.06         Down      
  hsa-miR-3130-3p     hsa-mir-3130-2   1.13               4.59                −4.06         Down      
  hsa-miR-3167        hsa-mir-3167     2.93               6.08                −2.08         Down      
  hsa-miR-3176        hsa-mir-3176     9.34               22.94               −2.46         Down      
  hsa-miR-33b-3p      hsa-mir-33b      2.14               4.82                −2.25         Down      
  hsa-miR-3615        hsa-mir-3615     4.95               15.71               −3.17         Down      
  hsa-miR-3619-5p     hsa-mir-3619     1.13               4.01                −3.55         Down      
  hsa-miR-377-5p      hsa-mir-377      6.53               13.30               −2.04         Down      
  hsa-miR-4454        hsa-mir-4454     3.04               6.31                −2.08         Down      
  hsa-miR-483-5p      hsa-mir-483      1.69               5.05                −2.99         Down      
  hsa-miR-487a-5p     hsa-mir-487a     1.35               3.10                −2.30         Down      
  hsa-miR-503-5p      hsa-mir-503      4.28               10.44               −2.44         Down      
  hsa-miR-541-3p      hsa-mir-541      2.14               7.46                −3.49         Down      
  hsa-miR-548d-5p     hsa-mir-548d-1   2.59               11.70               −4.52         Down      
  hsa-miR-548d-5p     hsa-mir-548d-2   3.26               13.65               −4.19         Down      
  hsa-miR-548n        hsa-mir-548n     2.81               5.73                −2.04         Down      
  hsa-miR-548o-3p     hsa-mir-548o     13.73              27.87               −2.03         Down      
  hsa-miR-548o-3p     hsa-mir-548o-2   13.73              27.87               −2.03         Down      
  hsa-miR-551b-3p     hsa-mir-551b     1.13               2.87                −2.54         Down      
  hsa-miR-6840-5p     hsa-mir-6840     1.46               2.98                −2.04         Down      
  hsa-miR-6852-5p     hsa-mir-6852     2.03               4.36                −2.15         Down      
  hsa-miR-877-5p      hsa-mir-877      9.00               18.24               −2.03         Down      
  hsa-miR-887-5p      hsa-mir-887      1.01               3.10                −3.07         Down      
  hsa-miR-92a-1-5p    hsa-mir-92a-1    1.35               4.01                −2.97         Down      
  hsa-miR-93-3p       hsa-mir-93       1.58               7.57                −4.79         Down      

miRNA/miR, microRNA; Up, upregulated; Down, downregulated.

###### 

Genes selected by intersection between RNA sequencing candidates and microRNA putative targets.

  Official gene symbol   Gene name                                        Log~2~ ratio (hypoxia/control)   Gene expression   miRNA with putative interaction
  ---------------------- ------------------------------------------------ -------------------------------- ----------------- ---------------------------------
  *SLC6A13*              Solute carrier family 6 member 13                11.77                            Up                hsa-miR-3619-5p
  *HIF3A*                Hypoxia inducible factor 3 α subunit             3.29                             Up                hsa-miR-1254,
                                                                                                                             hsa-miR-377-5p,
                                                                                                                             hsa-miR-615-5p
  *EPB49*                Dematin actin binding protein                    2.60                             Up                hsa-miR-1254
  *APLN*                 Apelin                                           2.16                             Up                hsa-miR-3619-5p,
                                                                                                                             hsa-miR-503-5p
  *ACVRL1*               Activin A receptor like type 1                   2.11                             Up                hsa-miR-3619-5p
  *SLC2A5*               Solute carrier family 2 member 5                 1.98                             Up                hsa-miR-3619-5p
  *STC1*                 Stanniocalcin 1                                  1.77                             Up                hsa-miR-541-3p,
                                                                                                                             hsa-miR-615-5p
  *SLC6A8*               Solute carrier family 6 member 8                 1.64                             Up                hsa-miR-541-3p
  *TNS1*                 Tensin 1                                         1.41                             Up                hsa-miR-3176
  *CAMK1D*               Calcium/calmodulin dependent protein kinase ID   1.24                             Up                hsa-miR-1254
  *C1QL1*                Complement C1q like 1                            1.20                             Up                hsa-miR-541-3p
  *GPR68*                G protein-coupled receptor 68                    1.14                             Up                hsa-miR-4741
  *CD4*                  CD4 molecule                                     1.13                             Up                hsa-miR-4741
  *MME*                  Membrane metalloendopeptidase                    1.09                             Up                hsa-miR-1303
  *BNIP3L*               BCL2 interacting protein 3 like                  1.08                             Up                hsa-miR-93-3p
  *APOL6*                Apolipoprotein L6                                −1.09                            Down              hsa-miR-4421
  *METTL7A*              Methyltransferase like 7A                        −1.13                            Down              hsa-miR-4421
  *TFRC*                 Transferrin receptor                             −1.17                            Down              hsa-miR-296-5p
  *BCL2*                 BCL2, apoptosis regulator                        −1.26                            Down              hsa-miR-296-5p
  *CHAC1*                Chac glutathione specific                        −1.44                            Down              hsa-miR-3918
                         γ-glutamylcyclotransferase 1                                                                        
  *DIO2*                 Iodothyronine deiodinase 2                       −1.48                            Down              hsa-miR-4717-3p
  *SLC7A11*              Solute carrier family 7 member 11                −1.50                            Down              hsa-miR-3129-3p,
                                                                                                                             hsa-miR-4768-5p,
                                                                                                                             hsa-miR-3074-5p,
                                                                                                                             hsa-miR-590-3p
  *TMEM144*              Transmembrane protein 144                        −1.84                            Down              hsa-miR-582-3p
  *HDAC11*               Histone deacetylase 11                           −2.11                            Down              hsa-miR-3918,
                                                                                                                             hsa-miR-766-3p

miR, microRNA.

###### 

Top three networks associated with genes targeted by microRNAs differentially expressed in hypoxic AC16 cardiomyocytes.

  Network   Top diseases and functions                                                                        Score   Focus molecules   Molecules in network
  --------- ------------------------------------------------------------------------------------------------- ------- ----------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  1         Free radical scavenging, small molecule biochemistry, carbohydrate metabolism                     32      14                [a](#tfn3-ijmm-42-05-2489){ref-type="table-fn"}*APLN*, [a](#tfn3-ijmm-42-05-2489){ref-type="table-fn"}*APOL6*, [a](#tfn3-ijmm-42-05-2489){ref-type="table-fn"}*BCL2*, *CAT*, [a](#tfn3-ijmm-42-05-2489){ref-type="table-fn"}*CD4*, *Cg*, [a](#tfn3-ijmm-42-05-2489){ref-type="table-fn"}*CHAC1*, *CTNNB1*, [a](#tfn3-ijmm-42-05-2489){ref-type="table-fn"}*DIO2*, [a](#tfn3-ijmm-42-05-2489){ref-type="table-fn"}*DMTN*, *EPAS1*, *F13A1*, *FBXO31*, *G0S2*, [a](#tfn3-ijmm-42-05-2489){ref-type="table-fn"}*HDAC11*, [a](#tfn3-ijmm-42-05-2489){ref-type="table-fn"}*HIF3A*, *IFNG*, *IL17RB*, *LAP3*, *MAPK1*, *MICU1*, [a](#tfn3-ijmm-42-05-2489){ref-type="table-fn"}*MME*, *NFkB(complex)*, *NRP2*, *SEC22B*, *SERPINB8*, *SLC16A3*, [a](#tfn3-ijmm-42-05-2489){ref-type="table-fn"}*SLC2A5*, [a](#tfn3-ijmm-42-05-2489){ref-type="table-fn"}*SLC6A8*, [a](#tfn3-ijmm-42-05-2489){ref-type="table-fn"}*STC1*, *SULF2*, [a](#tfn3-ijmm-42-05-2489){ref-type="table-fn"}*TFRC*, *TNF*, *TNFSF4*, *UTP18*
  2         Cancer, organismal injury and abnormalities, cell death and survival                              13      7                 [a](#tfn3-ijmm-42-05-2489){ref-type="table-fn"}*ACVRL1*, *BMP4*, [a](#tfn3-ijmm-42-05-2489){ref-type="table-fn"}*BNIP3L*, *C5*, *CD74*, *CREBBP*, *CXCL8*, *ESR1*, *F3*, *FOXO1*, *GDF2*, [a](#tfn3-ijmm-42-05-2489){ref-type="table-fn"}*GPR68*, *ID1*, *Iga*, *IGF1*, *Igm*, *IKBKE*, *ITGAM*, *KITLG*, [a](#tfn3-ijmm-42-05-2489){ref-type="table-fn"}*METTL7A*, [a](#tfn3-ijmm-42-05-2489){ref-type="table-fn"}*MME*, *MMP14*, *NCOR2*, *S100A6*, *SERPINB5*, [a](#tfn3-ijmm-42-05-2489){ref-type="table-fn"}*SLC7A11*, *SMAD2*, *SMARCA2*, *SMARCA4*, *SMARCE1*, *SOX2*, *STAT3*, *TLR2*, *TLR4*, [a](#tfn3-ijmm-42-05-2489){ref-type="table-fn"}*TNS1*
  3         Carbohydrate metabolism, small molecule biochemistry, digestive system development and function   2       1                 [a](#tfn3-ijmm-42-05-2489){ref-type="table-fn"}*CAMK1D*, *ERG*, *GCG*, *INS*

Focus molecules.

###### 

Kyoto Encyclopedia of Genes and Genomes pathway analysis of the dysregulated genes (top 20) identified from mRNA sequencing.

  Description                              Count P   -value   Gene upregulated                Gene downregulated                  Fold enrichment
  ---------------------------------------- --------- -------- ------------------------------- ----------------------------------- -----------------
  Legionellosis                            4         0.02     *ITGB2*, *EEF1A2*, *BNIP3*      *CXCL2*                             7.11
  Regulation of lipolysis in adipocytes    4         0.02     *AQP7*, *PTGS2*                 *ADORA1*, *PIK3R3*                  6.86
  Glycolysis/gluconeogenesis               4         0.03     *LDHA*, *TPI1*, *PGK1*          *LDHC*                              5.73
  Cysteine and methionine metabolism       3         0.06     *LDHA*                          *SDSL*, *LDHC*                      7.58
  Adrenergic signaling in cardiomyocytes   5         0.06     *CACNG6*, *RAPGEF4*,            *BCL2*, *PIK3R3*                    3.29
                                                              *PPP2R5B*                                                           
  Biosynthesis of antibiotics              6         0.07     *LDHA*, *TPI1*, *PGK1*, *RGN*   *SDSL*, *LDHC*                      2.72
  HIF-1 signaling pathway                  4         0.08     *VEGFA*                         *TFRC*, *BCL2*, *PIK3R3*            3.92
  Insulin resistance                       4         0.10     *PPP1R3B*, *PPP1R3C*            *PPARGC1A*, *PIK3R3*                3.55
  Carbon metabolism                        4         0.11     *TPI1*, *PGK1*, *RGN*           *SDSL*                              3.40
  Sphingolipid signaling pathway           4         0.13     *PPP2R5B*                       *ADORA1*, *BCL2 PIK3R3*             3.20
  VEGF signaling pathway                   3         0.13     *VEGFA*, *PTGS2*                *PIK3R3*                            4.72
  AMPK signaling pathway                   4         0.13     *PFKFB4*, *PPP2R5B*             *PPARGC1A*, *PIK3R3*                3.15
  Insulin signaling pathway                4         0.17     *PPP1R3B*, *PPP1R3C*            *PPARGC1A*, *PIK3R3*                2.78
  Rap1 signaling pathway                   5         0.17     *ITGB2*, *VEGFA*, *RAPGEF4*,    *PIK3R3*                            2.29
  Biosynthesis of amino acids              3         0.18     *TPI1*, *PGK1*                  *SDSL*                              3.89
  Hepatitis B                              4         0.19                                     *BCL2*, *TLR3*, *PIK3R3*, *IFIH1*   2.65
  Hematopoietic cell lineage               3         0.22     *MME*, *CD4*                    *TFRC*                              3.39
  Small cell lung cancer                   3         0.22     *PTGS2*                         *BCL2*, *PIK3R3*                    3.39
  Oxytocin signaling pathway               4         0.22     *PTGS2*, *CACNG6*, *CAMK1D*     *PIK3R3*                            2.43

Significant values are shown in bold.
